Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.

Cancer Causes & Control : CCC
Harvey J MurffMarie R Griffin

Abstract

Several observational studies suggest that metformin reduces incidence cancer risk; however, many of these studies suffer from time-related biases and several cancer outcomes have not been investigated due to small sample sizes. We constructed a propensity score-matched retrospective cohort of 84,434 veterans newly prescribed metformin or a sulfonylurea as monotherapy. We used Cox proportional hazard regression to assess the association between metformin use compared to sulfonylurea use and incidence cancer risk for 10 solid tumors. We adjusted for clinical covariates including hemoglobin A1C, antihypertensive and lipid-lowering medications, and body mass index. Incidence cancers were defined by ICD-9-CM codes. Among 42,217 new metformin users and 42,217 matched-new sulfonylurea users, we identified 2,575 incidence cancers. Metformin was inversely associated with liver cancer (adjusted hazard ratio [aHR] = 0.44, 95% CI 0.31, 0.64) compared to sulfonylurea. We found no association between metformin use and risk of incidence bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, or renal cancer when compared to sulfonylurea use. In this large cohort study that accounted for time-related biases, we observed ...Continue Reading

References

Oct 31, 2003·American Journal of Epidemiology·Wayne A Ray
Dec 13, 2005·Nature Reviews. Cancer·Marie-France DemierreScott M Lippman
Aug 19, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jaana KuoppalaEero Pukkala
May 6, 2010·Molecular Cancer Therapeutics·Issam Ben SahraFrédéric Bost
Jul 27, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mathilde JalvingElisabeth G E de Vries
Sep 22, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·J G BoyleG A McKay
Oct 16, 2010·Cancer Prevention Research·Andrea DecensiSara Gandini
Jan 20, 2012·Kidney International·Adriana M HungMarie R Griffin
Apr 24, 2012·The Journal of Clinical Endocrinology and Metabolism·Zhi-Jiang ZhangKevin E Kip
Aug 1, 2012·Breast Cancer Research and Treatment·Nananda F ColRowan T Chlebowski
Oct 12, 2012·Arthritis and Rheumatism·Kevin HaynesUNKNOWN SABER Collaboration
Nov 10, 2012·Scandinavian Journal of Gastroenterology·Hui ZhangShu-Kun Yao
Nov 23, 2012·Diabetes Care·Samy Suissa, Laurent Azoulay
Jan 29, 2013·Cancer Epidemiology·Pengpeng ZhangShumei Wang
Feb 6, 2013·The American Journal of Gastroenterology·Siddharth SinghWilliam Sanchez
Jan 8, 2014·Nature Reviews. Endocrinology·Ida Pernicova, Márta Korbonits
Jun 26, 2014·Diabetes Care·Samy Suissa, Laurent Azoulay
Jul 16, 2014·The Biochemical Journal·Hannah R BridgesJudy Hirst
Jun 9, 2015·World Journal of Hepatology·Javier Ampuero, Manuel Romero-Gomez

❮ Previous
Next ❯

Citations

Oct 22, 2019·Current Medical Research and Opinion·Aleksandra Berkan-Kawińska, Anna Piekarska
Nov 16, 2018·Expert Review of Clinical Immunology·Rolf Ak StahlElion Hoxha
Dec 11, 2019·The American Journal of Gastroenterology·Qiao-Li WangShao-Hua Xie
Jun 28, 2020·International Journal of Colorectal Disease·Cheng-Ann Winston NgChin Meng Khoo
Nov 20, 2019·Cancers·Ram C ShankaraiahMassimo Negrini
Jun 23, 2020·Clinical and Translational Gastroenterology·S Scott SuttonJames W Hardin
Oct 9, 2019·British Journal of Cancer·Jiaojiao ZhengJesper Lagergren
Dec 13, 2019·Journal of Diabetes Research·Abraham Nigussie MekuriaKirubel Minsamo Mishore
May 22, 2019·International Journal of Cancer. Journal International Du Cancer·Kim Tu TranAaron P Thrift
Feb 16, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Y ShuaiX Zhou
Dec 31, 2019·BioMed Research International·Lin JiatingZhang Yinchang
May 14, 2020·Analytical Cellular Pathology (Amsterdam)·Chidiebere V UgwuezeBasil C Ezeokpo
Jul 29, 2020·International Journal of Colorectal Disease·Wen-Tao YangJia-Le Liu
Sep 4, 2020·Pharmacology Research & Perspectives·Katherine N BachmannRosette J Chakkalakal
Jun 9, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·H-D WuB-J Zhou
Dec 11, 2019·Pathology, Research and Practice·Min DengHonghe Zhang
Feb 2, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Guangli LuChuning Zhang
Jan 17, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Yong-Bo WangYing-Hui Jin
Nov 22, 2020·Canadian Journal of Diabetes·Charupong SaengboonmeeSopit Wongkham
Jun 1, 2021·Gastrointestinal Endoscopy Clinics of North America·Shailja C Shah, Richard M Peek
Jul 1, 2021·JHEP Reports : Innovation in Hepatology·Zobair M Younossi, Linda Henry
Aug 1, 2021·Clinics and Research in Hepatology and Gastroenterology·Qiaomei LiHongjuan Zhang
Aug 28, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sherin AbdelrahmanJoanna Izabela Lachowicz

❮ Previous
Next ❯

Software Mentioned

R
SAS
rms

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.